美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

PagerDuty, Inc.

12.43

+0.11000.89%

成交量：3.18万

成交额：39.26万

市值：9.59亿

市盈率：5.87

高：12.45

开：12.32

低：12.29

收：12.32

52周最高：17.29

52周最低：5.70

股本：7,712.26万

流通股本：6,958.40万

量比：0.70

换手率：0.05%

股息：- -

股息率：- -

每股收益(TTM):2.12

每股收益(LYR):1.87

净资产收益率：94.62%

总资产收益率：1.82%

市净率：4.43

市盈率(LYR):6.65

数据加载中...

总览公司新闻资讯公告

维立志博-B(09887)：维利信™(奥帕替苏米单抗，PD-L1/4–1BB双特异性抗体，LBL-024)新药上市申请获NMPA受理

把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA，PD-1耐药黑色素瘤迎来新一代免疫重启方案

复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准

君实生物：JS207（PD-1/VEGF双抗）正处于II期临床研究阶段

减肥药重走PD-1老路，“白菜价药王”要来？

无问芯穹夏立雪：随着跨集群异构PD分离架构规模化落地，推理成本仍有10倍下降空间

基石药业-B(02616)：ESMO 2026预告-更多临床数据进一步验证 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)临床潜力与全球开发前景

科伦博泰TROP2 ADC实现“全球首个”：PD-L1阴性一线NSCLC III期达PFS主要终点

每日经济新闻

科伦博泰生物(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌3期临床研究达到主要终点

安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选

环球市场播报

北京Token工厂，融资10亿

恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题

维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)获纳入优先审评审批程序用于治疗晚期肺外神经内分泌癌

和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究

先声药业(02096)：SIM0689(PD-1/VEGF双特异性抗体)获国家药品监督管理局签发药物临床试验批准通知书

西南证券：PD~(L)1经治后耐药困局不容忽视 2026年催化密集

智通财经网

肿瘤免疫之王要变了？康方生物依沃西在OS数据上战胜PD-1单抗

港股异动 | 康方生物(09926)高开逾9% 依沃西联合化疗战胜PD-1联合化疗OS结果发布

中国创新药迎高光！康方生物核心产品战胜PD-1联合化疗总生存期结果

每日经济新闻

维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)治疗晚期肺外神经内分泌癌的III期临床研究获得CDE批准

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/PD/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":12.43,"timestamp":1787579090767,"preClose":12.32,"halted":0,"volume":31789,"delay":0,"changeRate":0.008928571428571383,"floatShares":69584020,"shares":77122565,"eps":2.117667,"marketStatus":"交易中","change":0.11,"latestTime":"08-24 09:44:58 EDT","open":12.32,"high":12.45,"low":12.285,"amount":392576.475316,"amplitude":0.013393,"askPrice":12.33,"askSize":235,"bidPrice":12.28,"bidSize":200,"shortable":3,"etf":0,"ttmEps":2.117667,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":12.32,"preHourTrading":{"tag":"盘前","latestPrice":12.38,"preClose":12.32,"latestTime":"08:26 EDT","volume":91,"amount":1121.4200270000001,"timestamp":1787574415826,"change":0.06,"changeRate":0.00487,"amplitude":0.00487},"postHourTrading":{"tag":"盘后","latestPrice":12.32,"preClose":12.32,"latestTime":"19:51 EDT","volume":324904,"amount":4002822.49,"timestamp":1787356261145,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.695667,"impliedVol":0.9115,"impliedVolPercentile":0.6892},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","floatShares":69584020,"roa":"1.82%","roe":"94.62%","lyrEps":1.87,"volumeRatio":0.695667,"shares":77122565,"dividePrice":0,"high":12.45,"amplitude":0.013393,"preClose":12.32,"low":12.285,"week52Low":5.7,"pbRate":"4.43","psRate":"1.94","week52High":17.29,"institutionHeld":0,"latestPrice":12.43,"committee":-0.08046,"eps":2.117667,"divideRate":0,"volume":31789,"delay":0,"ttmEps":2.117667,"open":12.32,"prevYearClose":13.11,"prevWeekClose":12.32,"prevMonthClose":10.58,"prevQuarterClose":9.65,"fiveDayClose":11.7,"twentyDayClose":9.76,"sixtyDayClose":7.44,"earningDate":1787760000000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PD\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"PD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2026/07","expectedEps":0.12,"defaultRemindTime":1787860800000,"name":null,"time":"盘后","dateTimestamp":1787803200000,"actualEps":null},{"market":"US","date":"2026-05-28","symbol":"PD","fiscalQuarterEnding":"2026/04","expectedEps":0.03,"name":null,"time":"盘后","type":"earning","dateTimestamp":1779940800000,"reportTimeType":"post","actualEps":0.1},{"market":"US","date":"2026-03-12","symbol":"PD","fiscalQuarterEnding":"2026/01","expectedEps":0.04,"name":null,"time":"盘后","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2025-11-25","symbol":"PD","fiscalQuarterEnding":"2025/10","expectedEps":0.02,"name":null,"time":"盘后","type":"earning","dateTimestamp":1764046800000,"reportTimeType":"post","actualEps":0.15},{"date":"2025-09-03","symbol":"PD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/07","expectedEps":-0.02,"defaultRemindTime":1756929600000,"name":null,"time":"盘后","dateTimestamp":1756872000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.4444,"sell":0.2222,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.4444,"analysts":9,"updateTime":1784692800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PD","date":"2026-08-21","current":5.817723,"percent":0.959336,"low":-115.332138,"twenty":-29.6527,"median":-21.707843,"eighty":-16.923368,"high":9.29824,"avg":-24.319119,"sd":22.361067,"marketCap":934725487},"quantilePoints":[{"date":"2021-08-27","current":-43.743597,"twenty":-64.248374,"median":-45.492434,"eighty":-39.784241,"marketCap":3499575255},{"date":"2021-09-03","current":-42.390054,"twenty":-64.090797,"median":-45.440934,"eighty":-39.784241,"marketCap":4025995391},{"date":"2021-09-10","current":-39.410762,"twenty":-63.838675,"median":-45.357157,"eighty":-39.773852,"marketCap":3743037083},{"date":"2021-09-17","current":-42.488469,"twenty":-63.43184,"median":-45.291593,"eighty":-39.773852,"marketCap":4035342362},{"date":"2021-09-24","current":-41.531159,"twenty":-63.322968,"median":-45.131991,"eighty":-39.806871,"marketCap":3944421825},{"date":"2021-10-01","current":-37.845067,"twenty":-63.294318,"median":-44.969953,"eighty":-39.673042,"marketCap":3594335269},{"date":"2021-10-08","current":-35.304169,"twenty":-63.234694,"median":-44.895964,"eighty":-39.361418,"marketCap":3353013468},{"date":"2021-10-15","current":-36.968279,"twenty":-62.977151,"median":-44.757709,"eighty":-39.195032,"marketCap":3511062253},{"date":"2021-10-22","current":-37.567716,"twenty":-62.673,"median":-44.689179,"eighty":-39.048237,"marketCap":3567993805},{"date":"2021-10-29","current":-37.352992,"twenty":-62.144822,"median":-44.662724,"eighty":-38.884343,"marketCap":3547600413},{"date":"2021-11-05","current":-38.927633,"twenty":-61.970673,"median":-44.622066,"eighty":-38.780249,"marketCap":3697151952},{"date":"2021-11-12","current":-37.684024,"twenty":-61.914834,"median":-44.517265,"eighty":-38.690435,"marketCap":3579040225},{"date":"2021-11-19","current":-34.892615,"twenty":-61.891288,"median":-44.350719,"eighty":-38.663132,"marketCap":3313926135},{"date":"2021-11-26","current":-33.094304,"twenty":-61.87812,"median":-44.340807,"eighty":-38.647574,"marketCap":3143131480},{"date":"2021-12-03","current":-27.717262,"twenty":-61.851785,"median":-44.310434,"eighty":-38.490518,"marketCap":2632446965},{"date":"2021-12-10","current":-29.437491,"twenty":-61.634212,"median":-44.193031,"eighty":-38.342002,"marketCap":2964590848},{"date":"2021-12-17","current":-29.446029,"twenty":-61.446371,"median":-44.130431,"eighty":-38.122419,"marketCap":2965450648},{"date":"2021-12-23","current":-30.863263,"twenty":-61.141525,"median":-44.120926,"eighty":-37.910083,"marketCap":3108177469},{"date":"2021-12-31","current":-29.668005,"twenty":-60.679678,"median":-44.096614,"eighty":-37.767931,"marketCap":2987805451},{"date":"2022-01-07","current":-27.243339,"twenty":-60.561077,"median":-44.020576,"eighty":-37.685906,"marketCap":2743622214},{"date":"2022-01-14","current":-26.466422,"twenty":-60.402519,"median":-43.931787,"eighty":-37.609143,"marketCap":2665380403},{"date":"2022-01-21","current":-25.715117,"twenty":-60.229637,"median":-43.82863,"eighty":-37.535067,"marketCap":2589717991},{"date":"2022-01-28","current":-27.448241,"twenty":-60.179262,"median":-43.748751,"eighty":-37.457573,"marketCap":2764257417},{"date":"2022-02-04","current":-27.106738,"twenty":-60.125395,"median":-43.643849,"eighty":-37.310047,"marketCap":2729865412},{"date":"2022-02-11","current":-28.728874,"twenty":-59.884929,"median":-43.550718,"eighty":-37.143446,"marketCap":2893227437},{"date":"2022-02-18","current":-27.106738,"twenty":-59.724487,"median":-43.492185,"eighty":-36.968378,"marketCap":2729865412},{"date":"2022-02-25","current":-28.071482,"twenty":-59.678646,"median":-43.437917,"eighty":-36.905651,"marketCap":2827022827},{"date":"2022-03-04","current":-25.322389,"twenty":-59.583656,"median":-43.360924,"eighty":-36.834452,"marketCap":2550167185},{"date":"2022-03-11","current":-22.70136,"twenty":-59.306192,"median":-43.319423,"eighty":-36.766338,"marketCap":2286208545},{"date":"2022-03-18","current":-28.291592,"twenty":-59.172166,"median":-43.295217,"eighty":-36.444632,"marketCap":3040073042},{"date":"2022-03-25","current":-28.785804,"twenty":-59.048339,"median":-43.241759,"eighty":-36.064649,"marketCap":3093178556},{"date":"2022-04-01","current":-27.724464,"twenty":-59.048339,"median":-43.1764,"eighty":-35.678665,"marketCap":2979132288},{"date":"2022-04-08","current":-25.415442,"twenty":-58.958192,"median":-43.086807,"eighty":-35.293402,"marketCap":2731016361},{"date":"2022-04-14","current":-26.428171,"twenty":-58.866018,"median":-43.039133,"eighty":-34.945236,"marketCap":2839839136},{"date":"2022-04-22","current":-23.843687,"twenty":-58.778063,"median":-42.940117,"eighty":-34.48789,"marketCap":2562123414},{"date":"2022-04-29","current":-23.14693,"twenty":-58.704534,"median":-42.888728,"eighty":-33.407653,"marketCap":2487253345},{"date":"2022-05-06","current":-21.039181,"twenty":-58.614907,"median":-42.82356,"eighty":-33.196501,"marketCap":2260765197},{"date":"2022-05-13","current":-21.537198,"twenty":-58.533862,"median":-42.744231,"eighty":-33.138326,"marketCap":2314279623},{"date":"2022-05-20","current":-19.528801,"twenty":-58.506847,"median":-42.67719,"eighty":-32.784627,"marketCap":2098467346},{"date":"2022-05-27","current":-21.055509,"twenty":-58.47232,"median":-42.506172,"eighty":-32.56425,"marketCap":2262519768},{"date":"2022-06-03","current":-19.41561,"twenty":-58.365647,"median":-42.492303,"eighty":-32.253988,"marketCap":2285547362},{"date":"2022-06-10","current":-18.661968,"twenty":-58.119439,"median":-42.449993,"eighty":-31.627913,"marketCap":2196830881},{"date":"2022-06-17","current":-17.871017,"twenty":-57.794408,"median":-42.412967,"eighty":-30.853018,"marketCap":2103722495},{"date":"2022-06-24","current":-21.251213,"twenty":-57.545961,"median":-42.37641,"eighty":-30.527663,"marketCap":2501629088},{"date":"2022-07-01","current":-18.975364,"twenty":-57.27835,"median":-42.328632,"eighty":-30.205871,"marketCap":2233722883},{"date":"2022-07-08","current":-20.758734,"twenty":-57.119373,"median":-42.300639,"eighty":-29.937792,"marketCap":2443655942},{"date":"2022-07-15","current":-19.512613,"twenty":-57.022546,"median":-42.274674,"eighty":-29.686169,"marketCap":2296966315},{"date":"2022-07-22","current":-19.751391,"twenty":-56.538634,"median":-42.258991,"eighty":-29.576542,"marketCap":2325074507},{"date":"2022-07-29","current":-19.348454,"twenty":-55.37095,"median":-42.1379,"eighty":-29.489533,"marketCap":2277641933},{"date":"2022-08-05","current":-21.340755,"twenty":-54.581356,"median":-41.999461,"eighty":-29.249821,"marketCap":2512169660},{"date":"2022-08-12","current":-21.370602,"twenty":-54.282209,"median":-41.907002,"eighty":-28.899625,"marketCap":2515683184},{"date":"2022-08-19","current":-19.214141,"twenty":-54.164004,"median":-41.742363,"eighty":-28.761236,"marketCap":2261831075},{"date":"2022-08-26","current":-19.318607,"twenty":-54.013801,"median":-41.687142,"eighty":-28.490216,"marketCap":2274128409},{"date":"2022-09-02","current":-16.562766,"twenty":-53.825684,"median":-41.612639,"eighty":-28.401837,"marketCap":2096100841},{"date":"2022-09-09","current":-17.753369,"twenty":-53.67791,"median":-41.5952,"eighty":-28.368118,"marketCap":2246777593},{"date":"2022-09-16","current":-16.597991,"twenty":-53.584381,"median":-41.569297,"eighty":-28.257217,"marketCap":2100558733},{"date":"2022-09-23","current":-15.858267,"twenty":-53.533149,"median":-41.530643,"eighty":-28.105632,"marketCap":2006943000},{"date":"2022-09-30","current":-16.252786,"twenty":-53.345477,"median":-41.466004,"eighty":-27.873415,"marketCap":2056871391},{"date":"2022-10-07","current":-16.182337,"twenty":-53.110426,"median":-41.390601,"eighty":-27.717262,"marketCap":2047955607},{"date":"2022-10-14","current":-14.646529,"twenty":-52.79331,"median":-41.34773,"eighty":-27.636067,"marketCap":1853591514},{"date":"2022-10-21","current":-16.485271,"twenty":-52.578578,"median":-41.307589,"eighty":-27.328715,"marketCap":2086293479},{"date":"2022-10-28","current":-17.922449,"twenty":-52.484531,"median":-41.281723,"eighty":-27.012825,"marketCap":2268175475},{"date":"2022-11-04","current":-14.604259,"twenty":-52.445692,"median":-41.223096,"eighty":-26.683037,"marketCap":1848242043},{"date":"2022-11-11","current":-17.35885,"twenty":-52.440537,"median":-41.165581,"eighty":-26.46868,"marketCap":2196849202},{"date":"2022-11-18","current":-15.442613,"twenty":-51.97825,"median":-41.046215,"eighty":-26.415612,"marketCap":1954339874},{"date":"2022-11-25","current":-15.379208,"twenty":-51.971496,"median":-40.952393,"eighty":-26.24103,"marketCap":1946315669},{"date":"2022-12-02","current":-16.042428,"twenty":-51.941247,"median":-40.886211,"eighty":-26.002015,"marketCap":2129728606},{"date":"2022-12-09","current":-16.110204,"twenty":-51.872986,"median":-40.837833,"eighty":-25.713912,"marketCap":2138726192},{"date":"2022-12-16","current":-18.028246,"twenty":-51.7604,"median":-40.772608,"eighty":-25.598799,"marketCap":2393357876},{"date":"2022-12-23","current":-17.994359,"twenty":-51.70784,"median":-40.745253,"eighty":-25.338499,"marketCap":2388859083},{"date":"2022-12-30","current":-18.001136,"twenty":-51.570726,"median":-40.701201,"eighty":-25.184081,"marketCap":2389758841},{"date":"2023-01-06","current":-16.049206,"twenty":-51.363479,"median":-40.623172,"eighty":-24.85486,"marketCap":2130628364},{"date":"2023-01-13","current":-18.78733,"twenty":-51.102161,"median":-40.574619,"eighty":-24.231092,"marketCap":2494130839},{"date":"2023-01-20","current":-18.882216,"twenty":-50.978262,"median":-40.523325,"eighty":-23.99114,"marketCap":2506727459},{"date":"2023-01-27","current":-19.925957,"twenty":-50.965686,"median":-40.469321,"eighty":-23.312385,"marketCap":2645290284},{"date":"2023-02-03","current":-21.220466,"twenty":-50.951221,"median":-40.311267,"eighty":-22.57339,"marketCap":2817144176},{"date":"2023-02-10","current":-19.627745,"twenty":-50.890949,"median":-40.250171,"eighty":-21.596594,"marketCap":2605700905},{"date":"2023-02-17","current":-20.664708,"twenty":-50.876484,"median":-40.190227,"eighty":-21.430411,"marketCap":2743363971},{"date":"2023-02-24","current":-19.485417,"twenty":-50.857197,"median":-40.120759,"eighty":-21.251213,"marketCap":2586805975},{"date":"2023-03-03","current":-20.834146,"twenty":-50.688437,"median":-40.045986,"eighty":-21.055509,"marketCap":2765857936},{"date":"2023-03-10","current":-18.204462,"twenty":-50.646894,"median":-39.953806,"eighty":-20.967665,"marketCap":2416751599},{"date":"2023-03-17","current":-22.814647,"twenty":-50.628165,"median":-39.81605,"eighty":-20.881589,"marketCap":2929925462},{"date":"2023-03-24","current":-22.508745,"twenty":-50.547877,"median":-39.758269,"eighty":-20.937818,"marketCap":2890640524},{"date":"2023-03-31","current":-24.884826,"twenty":-50.538628,"median":-39.648544,"eighty":-20.967665,"marketCap":3195783993},{"date":"2023-04-06","current":-22.608341,"twenty":-50.398102,"median":-39.410762,"eighty":-20.985573,"marketCap":2903430969},{"date":"2023-04-14","current":-23.753697,"twenty":-50.260054,"median":-39.321908,"eighty":-21.029355,"marketCap":3050521084},{"date":"2023-04-21","current":-24.273021,"twenty":-50.211876,"median":-39.198908,"eighty":-21.041663,"marketCap":3117214118},{"date":"2023-04-28","current":-22.053448,"twenty":-50.10983,"median":-39.086878,"eighty":-21.052864,"marketCap":2832169920},{"date":"2023-05-05","current":-20.085339,"twenty":-50.030853,"median":-39.045525,"eighty":-21.029355,"marketCap":2579419472},{"date":"2023-05-12","current":-21.254175,"twenty":-50.011348,"median":-38.97946,"eighty":-20.981096,"marketCap":2729524925},{"date":"2023-05-19","current":-21.074906,"twenty":-49.936988,"median":-38.858126,"eighty":-20.935287,"marketCap":2706502616},{"date":"2023-05-26","current":-18.98821,"twenty":-49.739821,"median":-38.781427,"eighty":-20.865452,"marketCap":2438522942},{"date":"2023-06-02","current":-23.7011,"twenty":-49.634889,"median":-38.748697,"eighty":-20.83367,"marketCap":2555476271},{"date":"2023-06-09","current":-19.16437,"twenty":-49.587066,"median":-38.685442,"eighty":-20.780404,"marketCap":2066321490},{"date":"2023-06-16","current":-19.591955,"twenty":-49.518553,"median":-38.668128,"eighty":-20.758997,"marketCap":2112424156},{"date":"2023-06-23","current":-18.642716,"twenty":-49.490829,"median":-38.652026,"eighty":-20.740419,"marketCap":2010076237},{"date":"2023-06-30","current":-18.830853,"twenty":-49.425691,"median":-38.650282,"eighty":-20.728887,"marketCap":2030361410},{"date":"2023-07-07","current":-18.753888,"twenty":-49.321753,"median":-38.534252,"eighty":-20.640309,"marketCap":2022062930},{"date":"2023-07-14","current":-21.12271,"twenty":-49.135663,"median":-38.486364,"eighty":-20.586625,"marketCap":2277471700},{"date":"2023-07-21","current":-20.626711,"twenty":-49.077653,"median":-38.375503,"eighty":-20.595005,"marketCap":2223992607},{"date":"2023-07-28","current":-21.105606,"twenty":-49.061015,"median":-38.330676,"eighty":-20.595005,"marketCap":2275627593},{"date":"2023-08-04","current":-20.883262,"twenty":-49.007339,"median":-38.158206,"eighty":-20.613914,"marketCap":2251654207},{"date":"2023-08-11","current":-20.549746,"twenty":-48.954208,"median":-37.988814,"eighty":-20.586625,"marketCap":2215694127},{"date":"2023-08-18","current":-20.01954,"twenty":-48.941266,"median":-37.845067,"eighty":-20.541194,"marketCap":2158526822},{"date":"2023-08-25","current":-20.66947,"twenty":-48.894876,"median":-37.770349,"eighty":-20.506987,"marketCap":2228602874},{"date":"2023-09-01","current":-25.511357,"twenty":-48.832826,"median":-37.755599,"eighty":-20.541194,"marketCap":2375209352},{"date":"2023-09-07","current":-24.043412,"twenty":-48.807682,"median":-37.686377,"eighty":-20.560008,"marketCap":2238537799},{"date":"2023-09-14","current":-23.412009,"twenty":-48.750972,"median":-37.671633,"eighty":-20.577111,"marketCap":2179751687},{"date":"2023-09-22","current":-22.590183,"twenty":-48.595885,"median":-37.578261,"eighty":-20.58462,"marketCap":2103236431},{"date":"2023-09-28","current":-22.048981,"twenty":-48.583225,"median":-37.547623,"eighty":-20.587293,"marketCap":2052848336},{"date":"2023-10-05","current":-21.978825,"twenty":-48.576545,"median":-37.531928,"eighty":-20.595005,"marketCap":2046316545},{"date":"2023-10-11","current":-21.497757,"twenty":-48.562801,"median":-37.500901,"eighty":-20.605423,"marketCap":2001527127},{"date":"2023-10-20","current":-20.345196,"twenty":-48.534663,"median":-37.448341,"eighty":-20.589221,"marketCap":1894219146},{"date":"2023-10-27","current":-19.894194,"twenty":-48.514606,"median":-37.410785,"eighty":-20.580532,"marketCap":1852229066},{"date":"2023-11-03","current":-20.485508,"twenty":-48.433814,"median":-37.299311,"eighty":-20.506205,"marketCap":1907282726},{"date":"2023-11-10","current":-20.746087,"twenty":-48.370598,"median":-37.219715,"eighty":-20.506987,"marketCap":1931543661},{"date":"2023-11-17","current":-21.217133,"twenty":-48.32991,"median":-37.120374,"eighty":-20.524091,"marketCap":1975399966},{"date":"2023-11-24","current":-21.858558,"twenty":-48.320008,"median":-37.057747,"eighty":-20.549746,"marketCap":2035119191},{"date":"2023-11-30","current":-22.048981,"twenty":-48.252059,"median":-36.968279,"eighty":-20.57027,"marketCap":2052848336},{"date":"2023-12-07","current":-26.625426,"twenty":-48.121131,"median":-36.925787,"eighty":-20.578821,"marketCap":2015198621},{"date":"2023-12-15","current":-28.276615,"twenty":-48.00719,"median":-36.911135,"eighty":-20.582242,"marketCap":2140172179},{"date":"2024-01-05","current":-26.103359,"twenty":-47.918569,"median":-36.904212,"eighty":-20.585288,"marketCap":1975684923},{"date":"2024-01-12","current":-31.117632,"twenty":-47.865829,"median":-36.842529,"eighty":-20.591149,"marketCap":2355200212},{"date":"2024-01-19","current":-31.627558,"twenty":-47.844972,"median":-36.829603,"eighty":-20.601178,"marketCap":2393794988},{"date":"2024-01-26","current":-29.053645,"twenty":-47.78321,"median":-36.766338,"eighty":-20.619869,"marketCap":2198983265},{"date":"2024-02-02","current":-29.32075,"twenty":-47.731847,"median":-36.504107,"eighty":-20.628421,"marketCap":2219199576},{"date":"2024-02-09","current":-29.393596,"twenty":-47.672575,"median":-36.388531,"eighty":-20.635263,"marketCap":2224713115},{"date":"2024-02-16","current":-29.733547,"twenty":-47.618326,"median":-36.095963,"eighty":-20.635379,"marketCap":2250442965},{"date":"2024-02-23","current":-28.10664,"twenty":-47.602066,"median":-35.89466,"eighty":-20.635842,"marketCap":2127307254},{"date":"2024-03-01","current":-29.332891,"twenty":-47.570415,"median":-35.678665,"eighty":-20.651153,"marketCap":2220118499},{"date":"2024-03-08","current":-29.55143,"twenty":-47.518149,"median":-35.35785,"eighty":-20.660918,"marketCap":2236659117},{"date":"2024-03-15","current":-26.009561,"twenty":-47.49129,"median":-35.24315,"eighty":-20.664708,"marketCap":2126463652},{"date":"2024-03-22","current":-25.786705,"twenty":-47.380514,"median":-34.925503,"eighty":-20.66947,"marketCap":2108243640},{"date":"2024-03-28","current":-24.935846,"twenty":-47.342533,"median":-34.589879,"eighty":-20.66947,"marketCap":2038679948},{"date":"2024-04-05","current":-25.071983,"twenty":-47.312176,"median":-34.414946,"eighty":-20.689994,"marketCap":2049810139},{"date":"2024-04-12","current":-25.888808,"twenty":-47.269427,"median":-33.423363,"eighty":-20.697474,"marketCap":2116591283},{"date":"2024-04-19","current":-23.631195,"twenty":-47.158961,"median":-33.184171,"eighty":-20.697474,"marketCap":1932015619},{"date":"2024-04-26","current":-22.916473,"twenty":-46.951231,"median":-33.003753,"eighty":-20.698257,"marketCap":1873582118},{"date":"2024-05-03","current":-23.897861,"twenty":-46.656905,"median":-32.649248,"eighty":-20.698257,"marketCap":1953817432},{"date":"2024-05-10","current":-23.114516,"twenty":-46.598159,"median":-32.247909,"eighty":-20.698257,"marketCap":1889773514},{"date":"2024-05-17","current":-24.517522,"twenty":-46.43348,"median":-31.759443,"eighty":-20.698257,"marketCap":2004479038},{"date":"2024-05-24","current":-22.904066,"twenty":-46.181838,"median":-31.451512,"eighty":-20.698257,"marketCap":1872567685},{"date":"2024-05-31","current":-20.986625,"twenty":-46.068748,"median":-31.128449,"eighty":-20.698257,"marketCap":1715803469},{"date":"2024-06-07","current":-20.224161,"twenty":-45.830813,"median":-30.643949,"eighty":-20.66395,"marketCap":1892880316},{"date":"2024-06-14","current":-21.429439,"twenty":-45.725202,"median":-30.31849,"eighty":-20.645029,"marketCap":2005688335},{"date":"2024-06-21","current":-21.357939,"twenty":-45.671397,"median":-29.967092,"eighty":-20.641966,"marketCap":1998996334},{"date":"2024-06-28","current":-23.247571,"twenty":-45.51108,"median":-29.932669,"eighty":-20.635726,"marketCap":2175856364},{"date":"2024-07-05","current":-22.542789,"twenty":-45.42729,"median":-29.794252,"eighty":-20.635726,"marketCap":2109892353},{"date":"2024-07-12","current":-21.439653,"twenty":-45.27192,"median":-29.668005,"eighty":-20.635726,"marketCap":2006644335},{"date":"2024-07-15","current":-21.807365,"twenty":-45.165128,"median":-29.6527,"eighty":-20.635726,"marketCap":2041060341},{"date":"2024-08-02","current":-20.438659,"twenty":-44.67116,"median":-29.473821,"eighty":-20.619869,"marketCap":1912956320},{"date":"2024-08-09","current":-18.937169,"twenty":-44.592228,"median":-29.326821,"eighty":-20.554877,"marketCap":1772424296},{"date":"2024-08-16","current":-19.846234,"twenty":-44.342086,"median":-29.065787,"eighty":-20.488395,"marketCap":1857508310},{"date":"2024-08-23","current":-19.366166,"twenty":-44.293477,"median":-28.968658,"eighty":-20.439367,"marketCap":1812576303},{"date":"2024-08-30","current":-20.193518,"twenty":-44.126836,"median":-28.878841,"eighty":-20.396729,"marketCap":1890012316},{"date":"2024-09-06","current":-20.851386,"twenty":-44.070828,"median":-28.815003,"eighty":-20.350301,"marketCap":1731811836},{"date":"2024-09-13","current":-19.495653,"twenty":-43.902513,"median":-28.750118,"eighty":-20.261779,"marketCap":1619211496},{"date":"2024-09-20","current":-20.358392,"twenty":-43.724824,"median":-28.493474,"eighty":-20.244564,"marketCap":1690866258},{"date":"2024-09-27","current":-20.324779,"twenty":-43.52784,"median":-28.425739,"eighty":-20.226358,"marketCap":1688074514},{"date":"2024-10-04","current":-19.753355,"twenty":-43.367535,"median":-28.373476,"eighty":-20.209123,"marketCap":1640614867},{"date":"2024-10-11","current":-20.30237,"twenty":-43.311657,"median":-28.264591,"eighty":-20.195561,"marketCap":1686213351},{"date":"2024-10-18","current":-21.030656,"twenty":-43.248031,"median":-28.136018,"eighty":-20.195561,"marketCap":1746701137},{"date":"2024-10-25","current":-20.078282,"twenty":-43.248031,"median":-28.049113,"eighty":-20.145499,"marketCap":1667601725},{"date":"2024-10-31","current":-20.649706,"twenty":-43.248031,"median":-27.765641,"eighty":-20.132647,"marketCap":1715061372},{"date":"2024-11-08","current":-22.688907,"twenty":-43.252213,"median":-27.636067,"eighty":-20.132233,"marketCap":1884427173},{"date":"2024-11-15","current":-21.960621,"twenty":-43.252213,"median":-27.448241,"eighty":-20.132233,"marketCap":1823939387},{"date":"2024-11-22","current":-22.229527,"twenty":-43.231304,"median":-27.106738,"eighty":-20.132233,"marketCap":1846273338},{"date":"2024-11-29","current":-25.707412,"twenty":-43.145724,"median":-26.876224,"eighty":-20.132233,"marketCap":1914893729},{"date":"2024-12-06","current":-25.40483,"twenty":-43.145724,"median":-26.625426,"eighty":-20.132233,"marketCap":1892354961},{"date":"2024-12-13","current":-24.521289,"twenty":-43.145724,"median":-26.466422,"eighty":-20.132233,"marketCap":1826541758},{"date":"2024-12-20","current":-22.572657,"twenty":-43.145724,"median":-26.327469,"eighty":-20.132233,"marketCap":1681392092},{"date":"2024-12-27","current":-22.173248,"twenty":-43.145724,"median":-26.203648,"eighty":-20.132233,"marketCap":1651640919},{"date":"2025-01-03","current":-21.785943,"twenty":-43.145724,"median":-26.12294,"eighty":-20.132233,"marketCap":1622791296},{"date":"2025-01-10","current":-21.434947,"twenty":-43.151859,"median":-25.994723,"eighty":-20.130744,"marketCap":1596646325},{"date":"2025-01-17","current":-22.584761,"twenty":-43.151859,"median":-25.832017,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-24","current":-22.584761,"twenty":-43.151859,"median":-25.722549,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-31","current":-22.330591,"twenty":-43.151859,"median":-25.688138,"eighty":-20.130744,"marketCap":1663361078},{"date":"2025-02-07","current":-23.032583,"twenty":-43.151859,"median":-25.544418,"eighty":-20.130744,"marketCap":1715651020},{"date":"2025-02-14","current":-23.601438,"twenty":-43.151859,"median":-25.410136,"eighty":-20.130744,"marketCap":1758023904},{"date":"2025-02-21","current":-22.149042,"twenty":-43.151859,"median":-25.353801,"eighty":-20.130744,"marketCap":1649837817},{"date":"2025-02-28","current":-21.229191,"twenty":-43.151859,"median":-25.248903,"eighty":-20.130744,"marketCap":1581319962},{"date":"2025-03-07","current":-20.902402,"twenty":-43.157994,"median":-25.114351,"eighty":-20.129255,"marketCap":1556978093},{"date":"2025-03-14","current":-25.841364,"twenty":-43.157994,"median":-25.015259,"eighty":-20.118618,"marketCap":1407320673},{"date":"2025-03-21","current":-31.526661,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1716941957},{"date":"2025-03-28","current":-31.810986,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1732426315},{"date":"2025-04-04","current":-28.415807,"twenty":-43.157994,"median":-25.140052,"eighty":-20.118618,"marketCap":1547524873},{"date":"2025-04-11","current":-25.672904,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1398146368},{"date":"2025-04-17","current":-25.238054,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1374464410},{"date":"2025-04-25","current":-26.22483,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1428204238},{"date":"2025-05-02","current":-26.007405,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1416363259},{"date":"2025-05-09","current":-26.208105,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1427293394},{"date":"2025-05-16","current":-28.064582,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1528397138},{"date":"2025-05-23","current":-26.826931,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1460994642},{"date":"2025-05-30","current":-40.212905,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1483896395},{"date":"2025-06-06","current":-38.417271,"twenty":-42.89345,"median":-25.054079,"eighty":-20.118618,"marketCap":1417635735},{"date":"2025-06-13","current":-37.443101,"twenty":-42.85482,"median":-25.054079,"eighty":-20.118618,"marketCap":1381687885},{"date":"2025-06-20","current":-35.644634,"twenty":-42.692819,"median":-25.045717,"eighty":-20.116377,"marketCap":1315322623},{"date":"2025-06-27","current":-37.218293,"twenty":-42.4845,"median":-25.045717,"eighty":-20.116377,"marketCap":1373392227},{"date":"2025-07-03","current":-39.940973,"twenty":-42.385562,"median":-25.045717,"eighty":-20.116377,"marketCap":1473861860},{"date":"2025-07-11","current":-39.516335,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"marketCap":1458192284},{"date":"2025-07-18","current":-36.593825,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"marketCap":1350348733},{"date":"2025-07-25","current":-36.743697,"twenty":-42.001222,"median":-25.045717,"eighty":-20.116377,"marketCap":1355879172},{"date":"2025-08-01","current":-40.265697,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1485844477},{"date":"2025-08-08","current":-38.941825,"twenty":-41.552011,"median":-25.045717,"eighty":-20.116377,"marketCap":1436992270},{"date":"2025-08-15","current":-38.667059,"twenty":-41.27534,"median":-25.045717,"eighty":-20.116377,"marketCap":1426853133},{"date":"2025-08-22","current":-39.441399,"twenty":-41.020287,"median":-25.045717,"eighty":-20.116377,"marketCap":1455427065},{"date":"2025-08-29","current":-42.263994,"twenty":-40.940123,"median":-25.045717,"eighty":-20.116377,"marketCap":1559583657},{"date":"2025-09-05","current":-111.301894,"twenty":-40.946258,"median":-25.037354,"eighty":-20.114136,"marketCap":1545092897},{"date":"2025-09-12","current":-111.369065,"twenty":-41.159237,"median":-25.045717,"eighty":-20.116377,"marketCap":1546025361},{"date":"2025-09-19","current":-110.361504,"twenty":-41.502219,"median":-25.045717,"eighty":-20.116377,"marketCap":1532038401},{"date":"2025-09-26","current":-108.816577,"twenty":-41.627318,"median":-25.045717,"eighty":-20.116377,"marketCap":1510591728},{"date":"2025-10-03","current":-110.630187,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1535768257},{"date":"2025-10-10","current":-109.824138,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1524578689},{"date":"2025-10-17","current":-105.659553,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1466765919},{"date":"2025-10-24","current":-107.540334,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1492874912},{"date":"2025-10-31","current":-105.793895,"twenty":-41.746269,"median":-25.045717,"eighty":-20.116377,"marketCap":1468630847},{"date":"2025-11-07","current":-101.562139,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1409885613},{"date":"2025-11-14","current":-104.719163,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1453711422},{"date":"2025-11-21","current":-98.740968,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1370722124},{"date":"2025-11-28","current":6.997444,"twenty":-41.746269,"median":-24.978468,"eighty":-20.091839,"marketCap":1065227860},{"date":"2025-12-05","current":7.219871,"twenty":-41.569584,"median":-24.845699,"eighty":-20.051536,"marketCap":1099088196},{"date":"2025-12-12","current":7.833049,"twenty":-41.149298,"median":-24.524361,"eighty":-20.010479,"marketCap":1192432905},{"date":"2025-12-19","current":7.79698,"twenty":-40.783904,"median":-24.456235,"eighty":-19.933106,"marketCap":1186942040},{"date":"2025-12-26","current":7.839061,"twenty":-40.638471,"median":-24.290539,"eighty":-19.921421,"marketCap":1193348049},{"date":"2026-01-02","current":7.881142,"twenty":-40.445544,"median":-24.213538,"eighty":-19.883804,"marketCap":1199754059},{"date":"2026-01-09","current":7.616633,"twenty":-40.245714,"median":-24.133436,"eighty":-19.850083,"marketCap":1159487714},{"date":"2026-01-16","current":7.105652,"twenty":-40.140803,"median":-24.036721,"eighty":-19.806911,"marketCap":1081700456},{"date":"2026-01-23","current":6.738947,"twenty":-40.000922,"median":-23.900481,"eighty":-19.757821,"marketCap":1025876659},{"date":"2026-01-30","current":6.318139,"twenty":-39.844633,"median":-23.836174,"eighty":-19.718173,"marketCap":961816564},{"date":"2026-02-06","current":4.749124,"twenty":-39.429144,"median":-23.74822,"eighty":-19.674843,"marketCap":722963925},{"date":"2026-02-13","current":4.075831,"twenty":-39.135469,"median":-23.649661,"eighty":-19.608912,"marketCap":620467774},{"date":"2026-02-20","current":4.021727,"twenty":-38.923318,"median":-23.601935,"eighty":-19.561129,"marketCap":612231476},{"date":"2026-02-27","current":4.256177,"twenty":-38.673097,"median":-23.492961,"eighty":-19.508534,"marketCap":647922100},{"date":"2026-03-06","current":4.664962,"twenty":-38.60711,"median":-23.396809,"eighty":-19.489511,"marketCap":710151906},{"date":"2026-03-13","current":3.826831,"twenty":-38.317356,"median":-23.305813,"eighty":-19.445457,"marketCap":665309840},{"date":"2026-03-20","current":3.358288,"twenty":-37.997629,"median":-23.223191,"eighty":-19.406656,"marketCap":583851876},{"date":"2026-03-27","current":3.07113,"twenty":-37.726969,"median":-23.142007,"eighty":-19.330546,"marketCap":533928310},{"date":"2026-04-02","current":3.075998,"twenty":-37.531928,"median":-23.103807,"eighty":-19.288759,"marketCap":534774472},{"date":"2026-04-10","current":2.95432,"twenty":-37.33152,"median":-23.026783,"eighty":-19.228348,"marketCap":513620418},{"date":"2026-04-17","current":3.119801,"twenty":-37.141321,"median":-22.922472,"eighty":-19.200424,"marketCap":542389931},{"date":"2026-04-24","current":2.998124,"twenty":-36.968415,"median":-22.886122,"eighty":-19.150518,"marketCap":521235878},{"date":"2026-05-01","current":3.236611,"twenty":-36.792556,"median":-22.796862,"eighty":-19.059356,"marketCap":562697823},{"date":"2026-05-08","current":3.60651,"twenty":-36.546214,"median":-22.703577,"eighty":-18.989041,"marketCap":627006145},{"date":"2026-05-15","current":2.967148,"twenty":-36.114067,"median":-22.620757,"eighty":-18.890004,"marketCap":515850488},{"date":"2026-05-22","current":3.10823,"twenty":-35.890938,"median":-22.561376,"eighty":-18.847957,"marketCap":540378298},{"date":"2026-05-29","current":3.010498,"twenty":-35.390059,"median":-22.540072,"eighty":-18.78733,"marketCap":573791883},{"date":"2026-06-05","current":3.84405,"twenty":-34.84372,"median":-22.428622,"eighty":-18.581645,"marketCap":732664367},{"date":"2026-06-12","current":3.548665,"twenty":-32.834795,"median":-22.336643,"eighty":-18.476527,"marketCap":676364895},{"date":"2026-06-18","current":3.487969,"twenty":-32.200072,"median":-22.276208,"eighty":-18.281834,"marketCap":664796510},{"date":"2026-06-26","current":3.463691,"twenty":-31.676123,"median":-22.229527,"eighty":-18.139398,"marketCap":660169156},{"date":"2026-07-02","current":4.058507,"twenty":-31.506957,"median":-22.173248,"eighty":-18.004593,"marketCap":773539326},{"date":"2026-07-10","current":4.232501,"twenty":-31.379147,"median":-22.100628,"eighty":-17.925594,"marketCap":806702029},{"date":"2026-07-17","current":4.309382,"twenty":-30.85814,"median":-22.017878,"eighty":-17.790437,"marketCap":821355317},{"date":"2026-07-24","current":3.492016,"twenty":-30.583371,"median":-21.935122,"eighty":-17.680267,"marketCap":665567735},{"date":"2026-07-31","current":4.196084,"twenty":-30.20705,"median":-21.898647,"eighty":-17.533486,"marketCap":799760999},{"date":"2026-08-07","current":4.491469,"twenty":-29.939946,"median":-21.843368,"eighty":-17.408164,"marketCap":856060471},{"date":"2026-08-14","current":4.892059,"twenty":-29.794252,"median":-21.785943,"eighty":-17.253175,"marketCap":932411810},{"date":"2026-08-21","current":4.904198,"twenty":-29.6527,"median":-21.707843,"eighty":-16.923368,"marketCap":934725487}],"updateTime":1787537708158},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661904265","title":"维立志博-B(09887)：维利信™(奥帕替苏米单抗，PD-L1/4–1BB双特异性抗体，LBL-024)新药上市申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2661904265","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661904265?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 16:47","pubTimestamp":1787302051,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，中华人民共和国国家药品监督管理局药品审评中心已正式受理本公司自主研发的在研药物维利信单药治疗晚期经治肺外神经内分泌癌的新药上市申请。维利信是全球首个申报上市的PD-L1/4–1BB双特异性抗体，该申请已于2026年7月10日获CDE优先审评资格。该研究已于2025年8月完成全部96例EPNEC患者入组。维利信是一种同时靶向PD-L1与4–1BB的双特异性抗体，是具有潜在生存获益的泛肿瘤IO2.0基石疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","09887","IPOS","PD","HK0000252160.HKD","HK0000500386.USD","LU1169589451.USD","LU1169590202.USD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657904156","title":"把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA，PD-1耐药黑色素瘤迎来新一代免疫重启方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2657904156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657904156?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 14:59","pubTimestamp":1786085956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169590202.USD","BK4023","BK4585","REPL","PD","LABU","BK4139","BK4588","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655490356","title":"复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655490356","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655490356?lang=zh_cn&edition=fundamental","pubTime":"2026-07-31 16:33","pubTimestamp":1785486809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，注射用HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准。HLX43是由本公司利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子与本公司自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物，拟用于晚期/转移性实体瘤的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","PD","02696","HK0000320223.HKD","PSYK","BK4023","HK0000306701.USD","HK0000306685.HKD","HK0000165453.HKD","HK0000320264.USD","LU1169590202.USD","IBBJ","MDTX","BMED","BK1161","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861803","title":"君实生物：JS207（PD-1/VEGF双抗）正处于II期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861803","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861803?lang=zh_cn&edition=fundamental","pubTime":"2026-07-29 18:29","pubTimestamp":1785320940,"startTime":"0","endTime":"0","summary":"证券日报网讯7月29日，君实生物在互动平台回答投资者提问时表示，JS207（PD-1/VEGF双抗）正处于II期临床研究阶段，正在多个瘤种中开展与化疗、单抗、ADC等不同药物的联合探索。JS207与JS212（EGFR/HER3ADC）联合用药的II期临床试验正在进行。未来公司计划基于前期临床数据，将JS207快速推进至关键注册临床阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825220569.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825220569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","LU1169590202.USD","LU1169589451.USD","BK1583","PD","BK4023","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653874827","title":"减肥药重走PD-1老路，“白菜价药王”要来？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653874827","media":"健康凯歌","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653874827?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 09:23","pubTimestamp":1784683395,"startTime":"0","endTime":"0","summary":"一场减重大战，即将来临。走GCG/GLP-1双靶点路线的玛仕度肽，9毫克组60周减掉了18.55%。研究显示，80周最高剂量组减重28.3%，BMI≥35的对照组，104周减重甚至到了30.3%。此外，医保几轮谈判下来，PD-1的年治疗费用已经不要3万元，这已经不能单纯的算是降价了。疗效类似，再牛的“药王”也扛不住降价的仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8uwIsXpkDir","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["XLVI","IYH","PINK","FXH","NVOC","MEDI","FHLC","PD","PJP","THNR","RSPH","NBDS","LU1169589451.USD","CURE","TRUH","LU1169590202.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298475","title":"无问芯穹夏立雪：随着跨集群异构PD分离架构规模化落地，推理成本仍有10倍下降空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652298475?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 15:21","pubTimestamp":1784532097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169590202.USD","PD","LU1169589451.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652638792","title":"基石药业-B(02616)：ESMO 2026预告-更多临床数据进一步验证 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)临床潜力与全球开发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2652638792","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652638792?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 08:06","pubTimestamp":1784505987,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，公司核心资产之一CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的临床研究成果成功入选2026年欧洲肿瘤内科学会(ESMO)年会，并将以两项快速口头报告的形式呈现，分别涵盖CS2009在晚期非小细胞肺癌(NSCLC)以及转移性结直肠癌(mCRC)患者中的I/II期临床试验数据。目前，相关摘要标题已在ESMO官网公布。需说明的是，摘要中所呈现的数据仅截至2026年4月，旨在符合大会递交期限之要求。基石药业将于2026年10月23日至26日在西班牙马德里召开的ESMO年会现场，展示数据截止日期更临近会议时间的临床研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK4023","PD","LU1169589451.USD","LU1169590202.USD","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651246129","title":"科伦博泰TROP2 ADC实现“全球首个”：PD-L1阴性一线NSCLC III期达PFS主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651246129","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651246129?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 22:38","pubTimestamp":1784126286,"startTime":"0","endTime":"0","summary":"7月15日早间，科伦博泰（HK06990，股价536.50港元，市值1282.36亿港元）宣布其TROP2ADC药物芦康沙妥珠单抗（佳泰莱?）联合帕博利珠单抗（可瑞达?）一线治疗PD-L1阴性非鳞状非小细胞肺癌的III期研究（OptiTROP-Lung06）在期中分析中达到无进展生存期主要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807804934.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807804934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4211","NETL","BK4195","BK4080","LU1169589451.USD","ADC","BK4023","BK4231","PD","PFS","BK4134","III","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651348206","title":"科伦博泰生物(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌3期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651348206","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651348206?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 07:32","pubTimestamp":1784071939,"startTime":"0","endTime":"0","summary":"安全性方面，芦康沙妥珠单抗联合帕博利珠单抗的安全性特征与既往研究报告一致，未观察到新的安全性信号。目前，本公司已在中国开展9项注册性临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","LU1169589451.USD","PD","BK4023","06990","LU1169590202.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651104260","title":"安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选","url":"https://stock-news.laohu8.com/highlight/detail?id=2651104260","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651104260?lang=zh_cn&edition=fundamental","pubTime":"2026-07-14 22:38","pubTimestamp":1784039880,"startTime":"0","endTime":"0","summary":"安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。　　安捷伦表示，此次获批有助于标准化相关癌症的免疫治疗患者筛选流程，支持全球临床医生做出更精准的治疗决策。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfu8357115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1169590202.USD","LABU","BK4023","LU1169589451.USD","BK4585","PD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651187190","title":"北京Token工厂，融资10亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2651187190","media":"智东西","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651187190?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 17:25","pubTimestamp":1783934731,"startTime":"0","endTime":"0","summary":"半年内，该公司累计融资金额已超过10亿元。现阶段，该公司已有日处理万亿级Token产能项目落地投产。目前，趋境科技已有日均万亿级产能的AI Token工厂建成投产，部分成熟业务已实现盈利。结语：资本押注AI Token工厂近半年，资本市场持续加码趋境科技，趋境科技累计募资规模已超10亿元。未来，随着高品质AI Token工厂的规模化落地与国产异构算力的大规模商用，趋境科技或将有望在AI基础设施的新一轮角逐中，为行业提供更稳固的生产底座。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8ujJBxxAOKZ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["CHAT","LU1169590202.USD","BK4023","AIPO","VTHR","PD","ARTY","AGIX","QTOC","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907502","title":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907502","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650907502?lang=zh_cn&edition=fundamental","pubTime":"2026-07-10 14:49","pubTimestamp":1783666155,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4023","LU1169590202.USD","PD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901516","title":"维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)获纳入优先审评审批程序用于治疗晚期肺外神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901516","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650901516?lang=zh_cn&edition=fundamental","pubTime":"2026-07-10 12:32","pubTimestamp":1783657957,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，维利信单药治疗晚期肺外神经内分泌癌的生物制品上市许可申请，已获中华人民共和国国家药品监督管理局药品审评中心批准纳入优先审评审批程序。根据相关中国法规，获纳入优先审评审批程序的BLA审评时限为130个工作日，而常规审评程序则为200个工作日。维利信获纳入优先审评程序标志着其迈向商业化的重要里程碑，为其预期获批时间表提供了明确指引及确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","HK0000500386.USD","LU1169590202.USD","PD","BK1161","09887","LU1169589451.USD","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648220025","title":"和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648220025?lang=zh_cn&edition=fundamental","pubTime":"2026-07-02 08:06","pubTimestamp":1782950774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0708994859.HKD","LU2456880835.USD","LU2488822045.USD","BK4007","LU2476274720.SGD","AZN","IE00B543WZ88.USD","LU2237443382.USD","IE00BPRC5H50.USD","PD","LU0432979614.USD","IE00B3T34201.USD","LU1267930573.SGD","LU0109394709.USD","LU1169590202.USD","LU0889565916.HKD","LU2778985437.USD","BK4588","LU2236285917.USD","02256","BK4568","LU2476274308.USD","LU2237443622.USD","LU0029864427.USD","LU2237443549.SGD","LU2089984988.USD","LU2237443465.HKD","BK1161","LU1829250122.USD","LU2417539215.USD","BK4585","LU2237443978.SGD","BK4023","LU2237443895.HKD","LU0320765992.SGD","LU0058720904.USD","AZNH","LU0289739699.SGD","IE00B5MMRT66.SGD","LU2462157665.USD","LU0310800379.SGD","LU1169589451.USD","LU0128525929.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642293703","title":"先声药业(02096)：SIM0689(PD-1/VEGF双特异性抗体)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642293703","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642293703?lang=zh_cn&edition=fundamental","pubTime":"2026-06-12 21:02","pubTimestamp":1781269339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，集团自主研发的靶向PD-1/ VEGF的双特异性抗体SIM0689已获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展晚期实体瘤的临床试验。SIM0689是一种同时靶向程序性死亡受体1(PD-1)和血管内皮生长因子(VEGF)特殊表位的双特异性抗体，通过解除肿瘤细胞免疫抑制和抗血管生成，发挥强效的抗肿瘤活性。在多种人源化小鼠药效模型中，SIM0689在低剂量即展现出优异的抗肿瘤疗效，整体药效显著优于同类型分子，提示其在多种实体瘤中有广泛的应用前景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","BK1583","BK1191","02096","LU1169589451.USD","BK4023","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642407722","title":"西南证券：PD~(L)1经治后耐药困局不容忽视 2026年催化密集","url":"https://stock-news.laohu8.com/highlight/detail?id=2642407722","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642407722?lang=zh_cn&edition=fundamental","pubTime":"2026-06-11 15:52","pubTimestamp":1781164329,"startTime":"0","endTime":"0","summary":"目前康方生物AK104联合普络西单抗(VEGFR2单抗)，取得了目前IO经治肺癌已披露研究数据中最长的OS，mOS=16.7mo。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260611/20260611152451_49256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260611/20260611152451_49256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4023","BK0012","BK4588","L","PD","LU1169589451.USD","BK4107","LU0210528500.USD","LU1169590202.USD","BK0028","LU0053666078.USD","BK4585","BK0276","BK0183","BK0188","LU2487616109.SGD","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640598243","title":"肿瘤免疫之王要变了？康方生物依沃西在OS数据上战胜PD-1单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2640598243","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640598243?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 09:49","pubTimestamp":1780278578,"startTime":"0","endTime":"0","summary":"康方生物（09926.HK)的PD-1/VEGF双抗依沃西，在药物临床价值评估“金标准”OS（总生存期）上的数据如何，牵动业界以及资本市场的神经。6月1日，在2026年美国临床肿瘤学会（ASCO）年会上，康方生物公布了依沃西联合化疗对比替雷利珠单抗联合化疗，一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)III期HARMONi-6/AK112-306研究的OS显著阳性结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755507073.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755507073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","IE00B5MMRT66.SGD","LU0348825331.USD","LU0417516902.SGD","LU1720050803.USD","LU2778985437.USD","BK4023","LU2488822045.USD","LU2476274308.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU0348783233.USD","LU1794554557.SGD","09926","LU0348766576.USD","LU0348827113.USD","IE00B543WZ88.USD","LU1169589451.USD","BK1161","LU0540923850.HKD","LU0348735423.USD","LU2399975544.HKD","LU2476274720.SGD","LU0417516738.SGD","LU0634319403.HKD","LU0417516571.SGD","LU0348784397.USD","LU0348767384.USD","PD","LU1169590202.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640437984","title":"港股异动 | 康方生物(09926)高开逾9% 依沃西联合化疗战胜PD-1联合化疗OS结果发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2640437984","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640437984?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 09:24","pubTimestamp":1780277063,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物今日大幅高开，截至发稿，涨9.23%，报129港元，成交额3.62亿港元。消息面上，康方生物PD-1/VEGF双抗依沃西单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的III期HARMONi-6研究于ASCO大会全体会议公布最新结果。与替雷利珠单抗联合化疗相比，依沃西组患者死亡风险下降34%，OS达到统计学显著性，两年生存率64.7% vs 48.6%。HARMONi-6共入组532例患者，中央型鳞癌占比约63%，PD-L1 TPS＜1%患者占39%，多部位转移、肝转移及脑转移患者占比约33.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0540923850.HKD","LU1794554557.SGD","LU0348766576.USD","IE00BPRC5H50.USD","LU0348767384.USD","LU0417516571.SGD","LU0634319403.HKD","LU1169589451.USD","LU0561508036.HKD","LU0348825331.USD","LU2399975544.HKD","LU0348735423.USD","IE00B543WZ88.USD","BK4585","09926","LU2778985437.USD","LU0348784397.USD","LU2488822045.USD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0417516738.SGD","LU2476274720.SGD","BK1574","LU2476274308.USD","BK4588","LU1169590202.USD","BK1161","LU0348827113.USD","BK4023","LU1720050803.USD","LU0348783233.USD","LU0417516902.SGD","VXUS","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639136988","title":"中国创新药迎高光！康方生物核心产品战胜PD-1联合化疗总生存期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2639136988","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639136988?lang=zh_cn&edition=fundamental","pubTime":"2026-05-31 21:16","pubTimestamp":1780233368,"startTime":"0","endTime":"0","summary":"5月31日，《每日经济新闻》记者注意到，在2026年美国临床肿瘤学会（ASCO）年会上，康方生物（HK09926，股价118.10港元，市值1088亿港元）PD-1/VEGF双抗依沃西联合化疗对比替雷利珠单抗联合化疗，一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）III期HARMONi-6/AK112-306研究的OS（总生存期）显著阳性结果揭晓。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605313755214061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605313755214061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0417516902.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0634319403.HKD","LU1169589451.USD","LU1169590202.USD","LU0417516571.SGD","LU0561508036.HKD","LU0417516738.SGD","LU2476274720.SGD","LU0348783233.USD","LU0348825331.USD","LU1720050803.USD","BK1161","159992","LU0348784397.USD","LU2778985437.USD","09926","LU1794554557.SGD","LU0348735423.USD","LU0348766576.USD","IE00BPRC5H50.USD","06978","BK4023","LU2399975544.HKD","LU0348827113.USD","PD","IE00B543WZ88.USD","LU1961090484.USD","LU0348767384.USD","BK1574","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022270","title":"维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)治疗晚期肺外神经内分泌癌的III期临床研究获得CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636022270?lang=zh_cn&edition=fundamental","pubTime":"2026-05-19 07:18","pubTimestamp":1779146304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。奥帕替苏米单抗已在肺外神经内分泌癌、非小细胞肺癌、小细胞肺癌及胆道癌四个适应症的注册性或II 期临床试验中展示出全球首创或同类最优潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","BK4134","LU1223082519.USD","LU1223083913.SGD","PD","LU1223082196.USD","CDE","III","BK1161","BK4017","LU1169589451.USD","LU1169590202.USD","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}